The agency called for a 20 percent decrease in manufacturing for various prescription opioid painkillers next year, among other controlled substances. The proposal falls in line with other agency leaders’ and lawmakers’ attempts to reduce the nation’s opioid supply.
The DEA believes its proposed production quotas reflect the amount of opioids needed to meet the U.S.’s medical and scientific needs — along with other requirements — since
demand for the painkillers has dropped due to safety measures like prescription drug monitoring programs, according to Reuters
The public can comment on the DEA’s proposal for the next 30 days. To view the proposal, click here.
More articles on opioids:
Proposed House bill would expand physician access to patient addiction treatment history
DOJ launches pilot program to crackdown on illegal opioid prescriptions
Viewpoint: 4 ways to turn the tide of the opioid epidemic
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
